A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme ClinicalTrials.gov identifier: NCT00045968 UCLA IRB #: 11-000686
The purpose of the study is to determine the safety and efficacy of an investigational therapy called DCVax®-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at UCLA prior to surgical resection of the tumor. Patients will receive standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax®-L and the remaining one third will receive placebo. Patients randomized to placebo will have the option to receive DCVax-Brain in a crossover arm upon documented disease progression.
In order to enroll in this trial, patients must have surgery for a newly diagnosed tumor here at UCLA prior to radiation and chemotherapy. The tumor tissue is collected and processed immediately at the time of surgery in order to make the personalized vaccine. Due to strict FDA and sterility requirements, we unfortunately cannot accept tumor tissue that has already been resected and stored at outside institutions.
View DCVax Informational Flyer (PDF), View DCVax Consent (PDF)
Please note, this study is on hold for enrollment at this time.
For further information, please contact: Emma Billingslea-Yoon, N.P. at (310) 267-0373 or EBillingslea@mednet.ucla.edu
For a full list of our most updated clinical trials, please see the ClinicalTrials.gov website.